RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

BackgroundRH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for en...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Julie Healer, Jennifer K. Thompson, Karen L. Mackwell, Cecille D. Browne, Benjamin A. Seager, Anna Ngo, Kym N. Lowes, Sarah E. Silk, David Pulido, Lloyd D. W. King, Jayne M. Christen, Amy R. Noe, Vinayaka Kotraiah, Paul J. Masendycz, Rajkannan Rajagopalan, Leanne Lucas, Marianne M. Stanford, Lorraine Soisson, Carter Diggs, Robin Miller, Susan Youll, Kaye Wycherley, Simon J. Draper, Alan F. Cowman
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-12-01
Schriftenreihe:	Frontiers in Cellular and Infection Microbiology
Schlagworte:	malaria Plasmodium falciparum RH5 complex vaccine merozoite invasion Ripr
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fcimb.2022.1049065/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!